Trial
NCT03710941
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Sporadic Inclusion Body Myositis
Intervention
REGN2477+REGN1033
Why stopped
The study was withdrawn due to an internal decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-29